Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors

3500 Background: XL147 is a selective inhibitor of Class I PI3K isoforms. In preclinical cancer models XL147 is cytostatic or cytoreductive as monotherapy and enhances the efficacy of targeted agen...